Last reviewed · How we verify

Gastric Cancer — Treatment Landscape & Competitive Intelligence

Gastric Cancer (Oncology) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Oncology 1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Gastric Cancer, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Tevimbra TISLELIZUMAB Beigene Programmed Death Receptor-1 Blocking Antibody [EPC] Pd-1 2025-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Beigene · 1 drug in Gastric Cancer
  2. Pfizer Inc. · 1 drug in Gastric Cancer

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Gastric Cancer:

Cite this brief

Drug Landscape (2026). Gastric Cancer — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/gastric-cancer. Accessed 2026-05-16.

Related